Systemic scleroderma
Drug research and approvals for systemic scleroderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 151 studies of systemic scleroderma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 151
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 151 recruiting on ClinicalTrials.gov ↗- Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesNCT05029336 · Phase 2 · Stephan Grupp MD PhD · starts Nov 1, 2026
- Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)NCT07650565 · Not applicable · University Hospital, Montpellier · starts Oct 27, 2026
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
- A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it…NCT07649265 · Phase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Sep 24, 2026
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically…NCT07691970 · Phase 3 · AstraZeneca · starts Aug 31, 2026
- A Study to Test CRT-402 in Refractory Autoimmune DiseaseNCT07778446 · Phase 1 / Phase 2 · Myeloid Therapeutics · starts Aug 26, 2026
- A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisNCT07497087 · Phase 3 · Boehringer Ingelheim · starts Jul 27, 2026
- US Zamto-cel Autoimmune DiseasesNCT06708845 · Phase 1 · Miltenyi Biomedicine GmbH · starts Jul 1, 2026
- Immun4Cure Cohort of Autoimmune DiseasesNCT07515638 · Not reported · University Hospital, Montpellier · starts Jun 23, 2026
Drug pipeline
3 approved, 10 in phase 3, 30 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Bosentan, Tocilizumab, Nintedanib
- Cyclophosphamide anhydrous
- Phase 3 DNA inhibitor
- Filgrastim
- Phase 3 Granulocyte colony stimulating factor receptor agonist
- Fludarabine
- Phase 3
- 2-MERCAPTOETHANESULFONIC acid
- Phase 3 Unknown
- Relaxin
- Phase 3
- Macitentan
- Phase 3 Endothelin receptor, ET-A/ET-B antagonist
- Sildenafil
- Phase 3 Phosphodiesterase 5A inhibitor
- Rosuvastatin
- Phase 3 HMG-CoA reductase inhibitor
- Inebilizumab
- Phase 3 B-lymphocyte antigen CD19 binding agent
- Divozilimab
- Phase 3
- Rituximab
- Phase 2 B-lymphocyte antigen CD20 binding agent
- Mycophenolate mofetil
- Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Imatinib
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Sirolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Tacrolimus anhydrous
- Phase 2 FK506-binding protein 1A inhibitor
- Tofacitinib
- Phase 2 Janus Kinase (JAK) inhibitor
- Belimumab
- Phase 2 Tumor necrosis factor ligand superfamily member 13B inhibitor
- Pirfenidone
- Phase 2 Unknown
- Ziritaxestat
- Phase 2 Autotaxin inhibitor
- Fipaxalparant
- Phase 2
- GSK-2330811
- Phase 2
- Nilotinib
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Pomalidomide
- Phase 2 CRL4(CRBN) E3 ubiquitin ligase inhibitor
- Riociguat
- Phase 2 Soluble guanylate cyclase positive allosteric modulator
- Clopidogrel
- Phase 2 Purinergic receptor P2Y12 antagonist
- Human immunoglobulin g
- Phase 2 Replacement therapy, immunomodulatory effects
- Tadalafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Iloprost
- Phase 2 Prostanoid IP receptor agonist
- Plerixafor
- Phase 2 C-X-C chemokine receptor type 4 partial agonist
- Albumin human
- Phase 2 Bilirubin sequestering agent
Showing the 30 furthest along of 48 in trials.
How its trials ended
588 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 129 whose ending is known, 37% met their primary endpoint, 12% missed it and 51% stopped early.
- Completed, result not reported20635%
- Ongoing17029%
- Status unknown8314%
- Met its primary endpoint488%
- Stopped: other or unclear336%
- Stopped: enrollment or feasibility163%
- Missed its primary endpoint153%
- Stopped: sponsor or business decision81%
- Stopped: lack of efficacy61%
- Stopped: safety20%
- Stopped: funding10%
FDA orphan designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jul 6, 2017 | (1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(p…Treatment of systemic scleroderma (SSc) | Emerald Health Pharmaceuticals Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA